AstraZeneca Breast Cancer Drug Secures FDA Approvals
Igår, 09:42
03:42 AM EDT, 05/18/2026 (MT Newswires) -- AstraZeneca (AZN) said Friday the US Food and Drug Administration approved its Enhertu medication, developed with Daiichi Sankyo, to treat HER2-positive early breast cancer both before and following surgery.
The pre-surgery treatment demonstrated a 67.3% complete response rate compared to 56.3% for standard care, while the post-surgery application reduced the risk of disease recurrence or death by 53% in phase 3 trials, the company said.
No new safety issues were identified during the studies, AstraZeneca said.
The US authorizations trigger $155 million in milestone payments from AstraZeneca to Daiichi Sankyo, it added.
Ämnen i artikeln
AstraZeneca Breast Cancer Drug Secures FDA Approvals
Igår, 09:42
03:42 AM EDT, 05/18/2026 (MT Newswires) -- AstraZeneca (AZN) said Friday the US Food and Drug Administration approved its Enhertu medication, developed with Daiichi Sankyo, to treat HER2-positive early breast cancer both before and following surgery.
The pre-surgery treatment demonstrated a 67.3% complete response rate compared to 56.3% for standard care, while the post-surgery application reduced the risk of disease recurrence or death by 53% in phase 3 trials, the company said.
No new safety issues were identified during the studies, AstraZeneca said.
The US authorizations trigger $155 million in milestone payments from AstraZeneca to Daiichi Sankyo, it added.
Ämnen i artikeln
Evolution
Evolution
Marknadsöversikt
1 DAG %
Senast
1 mån
